Treated (n=529) | Untreated (n=864) | |
---|---|---|
HbA1c concentrations at the baseline examination, % | 7.7±1.6 | 7.7±1.7 |
HbA1 concentrations at the follow-up examination, % | 7.1±1.4 | 7.7±1.8 |
Change in HbA1c, % | −0.6±1.5 | 0.0±1.0 |
(A) Increase in HbA1c ≥0.5% concentrations | ||
Cases (%) | 72 (13.6) | 200 (23.1) |
Crude OR (95% CI) | 1 | 1.91 (1.42 to 2.57) |
Adjusted OR (95% CI)* | 1 | 1.87 (1.38 to 2.52) |
(B) Increase in HbA1c ≥1.0% concentrations | ||
Cases (%) | 39 (7.4) | 104 (12.0) |
Crude OR (95% CI) | 1 | 1.72 (1.17 to 2.53) |
Adjusted OR (95% CI)* | 1 | 1.63 (1.10 to 2.41) |
(C) Relative increase of ≥20% for baseline HbA1c concentrations† | ||
Cases (%) | 19 (3.6) | 52 (6.0) |
Crude OR (95% CI) | 1 | 1.72 (1.005 to 2.94) |
Adjusted OR (95% CI)‡ | 1 | 1.65 (0.96 to 2.85) |
*ORs were adjusted for age, sex, body mass index and HbA1c at the baseline health examination.
†Examples of relative increase of ≥20% for baseline HbA1c concentrations: having 6.5% at the baseline examination and ≥7.8% at the follow-up examination and 7% at the baseline examination and ≥8.4% at the follow-up examination.
.
‡OR was adjusted by age, sex and body mass index.
HbA1c, glycated haemoglobin.